BridgeBio has collaborated with two new academic institutions, Columbia University and Mount Sinai (Icahn Mount Sinai), to translate research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
“Columbia University and Mount Sinai are known for bringing together some of the most talented scientists to develop breakthroughs for patients. By partnering with these world-class research institutions, we are hopeful that together we will be able to help patients in need,” said BridgeBio founder and CEO Neil Kumar.
BridgeBio has initiated 25 collaborations with institutions around the world that are focused on providing therapeutic options to patients with unmet needs as quickly and safely as possible. BridgeBio says collaborating with academic institutions to identify early discoveries is a core pillar of its efforts to reach patients more quickly. The goal of these collaborations is to revolutionise the relationships between drug development companies and biomedical research institutions.
